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VISUAL HALLUCINATION DIFFERENTIAL DIAGNOSIS CHART
Abstract
Differential diagnosis of the etiology of visual hallucinations is challenging. Although visual
hallucinations can be symptomatic of psychiatric disorder, they more commonly indicate
neurological or medical disorders, sensory impairment, or substance intoxication or withdrawal.
Accurate diagnosis and treatment is crucial given that misdiagnosis and incorrect treatment
intervention can have profound consequences. The purpose of this paper is to summarize the
most prevalent causes of visual hallucinations, review the DSM-5 hallucination decision tree,
and provide an annotated visual hallucination differential diagnosis decision tree.
Keywords: Visual hallucination, differential diagnosis, decision tree
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Visual Hallucinations Differential Diagnosis Decision Tree
While I was training as a psychology graduate student on a neuropsychology practicum, a
patient presented for a neuropsychological evaluation with a personal history of visual
hallucinations. The referral question was to assess his current level of cognitive functioning and
to make a differential diagnosis. Rule outs included major depression with psychotic features and
dementia with Lewy bodies. If he had depression with psychotic features, psychiatry would
likely begin a trial of antipsychotic medication in addition to his antidepressant medication. If it
was determined to be dementia with Lewy bodies certain antipsychotics may be contraindicated.
Ultimately, it was determined that the patient had serotonergic syndrome after mixing
antidepressant medications with over-the-counter herbal supplements. He had initially denied
taking supplements, but subsequently acknowledged doing so after neuropsychological testing.
Visual hallucinations can be indicative of a wide range of disorders, both psychiatric and
non-psychiatric in nature. Visual hallucinations are one potential feature of psychosis, and a
psychology trainee should be well versed in the various non-affective and affective psychiatric
disorders that most commonly give rise to them, such as schizophrenia, bi-polar disorder, and
depression. However, a wide range of neurologic and medical conditions can present with visual
hallucinations, including seizures, metabolic or endocrine disorders, and infection, and these may
require immediate medical attention and specialized medical knowledge to adequately diagnose.
Visual hallucinations may also be related to substance intoxication or withdrawal, which may or
may not be comorbid with underlying psychiatric and/or non-psychiatric conditions. Visual
hallucinations may also be related to sleep disturbances. They may also fall into the realm of
normal experience, particularly if occurring immediately before or after sleep, or following the
death of a loved one (Teeple, Caplan, & Stern, 2009).
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Examining the potential etiologies of visual hallucinations regarding the case above made
me wish for a systematic visual hallucination differential diagnostic decision tree. This desire
prompted the idea for this paper; to present a beginning framework and questions to guide a
psychology trainee through the steps of what to consider at each decision tree juncture. This
experience also prompted me to examine the process, potential for misdiagnosis, and logical
errors that may occur with differential diagnosis.
Diagnosis itself has many potential functions. Diagnosis should be valid and more
importantly useful (Kendall & Jablensky, 2003). Diagnosis has the greatest utility when it
informs evidence-based treatment options, identified in a timely manner (McGorry & van Os,
2013). Diagnosis may be used to label or to identify a condition or set of symptoms, provide
shorthand for clinicians to communicate with each other, and help with billing codification and
payment. Accurate diagnosis may help to promote understanding of the disorder and the
potential course of the disorder. Diagnosis may impact a patient's access to care. Diagnosis may
also be used to stigmatize.
Diagnoses from the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition, 2013), and to a lesser extent the ICD-10 (International Statistical Classification of
Diseases and Related Health Problems, Tenth Edition, 1990), often are used in a top down
approach. A clinician starts with the suspected diagnosis or diagnoses and then compares the
presentation, and if possible the course of the presentation and response to treatment. The top
down approach although often used, is not recommended because it is subject to confirmation
bias and assumes reliability within categories, which is often not the case.
Starting with a symptom, such as visual hallucinations, leads to a bottom to top approach
to diagnosis. In theory one would consider all of the possible etiologies of the symptom and
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work upwards towards differential diagnosis in a systematic manner attempting to recognize the
pattern of the symptom as it relates to potential diagnoses. The bottom-to-top approach would
not be useful if the symptom was common such as a headache, fever, or low mood. However,
with a symptom that is rare this approach is useful.
Beside this limitation, the bottom-to-top approach has several benefits and drawbacks.
This approach creates the potential for improved diagnostic accuracy. In addition, increased
awareness and understanding of the mechanisms underlying varying diagnoses with similar
symptomology, could potentially inform future research and treatment. Downsides include the
amount of additional time and expense it could take to make a diagnosis, which in many cases
may not be an available luxury. Another downside is the knowledge base required to approach a
diagnosis in this manner. Expecting a single clinician to have a substantial fund of knowledge of
all the potential diagnoses related to visual hallucination that occur across various fields and
disciplines is unrealistic.
Thus, creating a single decision tree is challenging. Given that visual hallucinations can
initially present to providers in many medical and mental health disciplines, including
psychiatry, psychology, neurology, neuropsychology, emergency medical services, primary care,
nursing, and assisted living, the interplay of these fields should be considered when making a
diagnosis. These field specialties each have their own approaches to problem solving and
different lenses through which to view differential diagnosis. Doctors may refer to psychiatry,
neuropsychology or psychology when the patient’s presentation does not fit the expected clinical
picture, just as neuropsychology and psychology may refer a patient to neurology if the clinical
picture is unclear and does not fit the expected pattern of presentation for a psychiatric disorder.
Respect for the bounds, capabilities, limitations, ethical considerations, and awareness of the
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assumptions of each field is warranted. However, a basic understanding of alternative
explanations for visual hallucination and the prevalence rates of those disorders may help to lead
to more accurate differential diagnosis and treatment. Therefore, information regarding the most
prevalent etiologies of visual hallucinations, and prevalence rates in the general population as
well as base rates in other more specific populations will be indicated when available.
The hallucination decision tree of the DSM-5 Handbook of Differential Diagnosis (see
Figure 1.0) (First, 2014) is used as an initial decision tree framework as applied to visual
hallucinations. In this paper I will address the value and utility of the model, as well as the
potential errors in clinical judgment, assessment, treatment, diagnosis, and logic this model may
inadvertently perpetuate when applied to visual hallucinations. Questions regarding what to
consider at each juncture of the decision tree will also be presented.
Prevalence Rates and Differential Diagnosis
It is important to remember the medical school saying attributed to Dr. Theodore
Woodward, “When you hear hoof beats, think horses not zebras” (Sotos, 2006, p1). As clinicians,
we increase our vulnerability to misdiagnosing if we do not sufficiently consider base rates and
acknowledge the limits of our clinical judgment (Karson & Nadkarni, 2013). In addition we are
vulnerable to making rare diagnoses rather than seeing the more common diagnoses due to the
availability heuristic; the phenomenon in which that which is more memorable stays in mind
more than that which is more probable and because “the striking and novel stays longer in mind”
(Sotos, 2006). We are also likely to look for a psychiatric condition rather than a medical
condition with psychiatric features due to the availability of our training and fund of knowledge
in psychology compared with the limited scope of our medical knowledge.
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Prevalence rates do not conclusively tell if the individual patient has the diagnosis.
Diagnosis depends on whether the individual patient has the disorder, not on a statistic based on
the group (Harvey et.al, 1979). However, given that there are usually alternate diagnoses to
which the patient’s symptoms may fulfill diagnostic criteria, the clinician needs to remember that
among those potential diagnoses, zebras and horses exist and may even be considered potential
rule-outs, particularly if the presentation of the course of the disorder is not as expected.
Prevalence rates may serve to remind the clinician what is statistically common in the group
studied; they may indicate whether if one is looking at a zebra or a horse. Put differently, in a
Bayesian analysis, an oddity in presentation or history changes the situation and requires a
different base rate. Thus, the patient above not having taken supplements would have put him in
a group where the base rate for the ultimate diagnosis was much lower than it was for the group
that taking supplements put him in. If you are in Tanzania, think zebras not horses.
Given the low prevalence/base rate of visual hallucinations, as well as the low base rates
of the many etiologies behind them, caution is advised regarding base-rate fallacy. A discussion
of base rates, Bayes theorem, base rate fallacy, and Sutton’s law is in order. Regarding base
rates, also called prevalence, it is important that the base rate/prevalence is the “naturally
occurring rate of a condition in a population” (American Psychological Association, 2007, p.
103). Base-rate fallacy is a decision-making error in which information about rate of occurrence
in a population (base rate information) is ignored or not given proper weight” (American
Psychological Association, 2007, p. 103). For example, if I told you we were going to a business
retreat island vacation and 90% of those on the island were psychologists and 10% were
morticians, one might assume a gentleman on the island with an interest in dead bodies was one
of the morticians and downplay the fact that 90% of the people are psychologists. “Bayes’
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theorem is a formula derived from probability theory that relates two conditional probabilities:
the probability of the event A, given that even B has occurred, p(A/B), and the probability of
event B given that event A has occurred, p(B/A). It serves as a basis for linking prior and
antecedent probabilities” (American Psychological Association, 2007, p. 105). The formula is as
follows p(A│B)= p(B│A) p(A)/ p(B│A) p(A) + p(B│~A) p(~A).
Suppose that a new blood test has been discovered that correctly identifies 90% of those
with schizophrenia as having it, but falsely identifies those without schizophrenia as having it
10% of the time. This sounds like a fairly good test, right? What do you intuitively assume the
probability that a person actually has schizophrenia given a positive test result? For simplicity’s
sake, assume that the prevalence rate of schizophrenia is 1% and A= an individual has
schizophrenia and B= a positive test result. The equation would be
(.90)(.01)/(.01)(.90)+(.99)(.10). The result would be an 8.3% chance of actually having
schizophrenia with a positive test result (because the a priori probability is so low). Thus,
intuitive judgment may get one into trouble with diagnosis. When the prevalence rate is so low
and the diagnostic gold standard is not clear, there is incredible room for incorrect diagnosis.
Clinicians also need to remember Sutton’s law, which states that a clinician should
conduct assessment regarding the most obvious diagnosis first, balancing it against the potential
of risk to the patient of not addressing another less common diagnosis (Rytand, 1980). In the
differential diagnosis of the etiology of visual hallucinations, one needs to remember there are
many zebras and a few horses, with the added concern that several of the diagnoses are
potentially fatal.
Regarding visual hallucinations, suppose the case of a 23 year old patient presenting at 2
o’clock in the morning at an ER in New Orleans during Mardi Gras; statistically the visual
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hallucinations are likely substance related, but not necessarily. Diagnosis could also be the onset
of schizophrenia, a head injury, infection, or one of many other etiologies. However, if the main
presenting feature is visual hallucinations without auditory hallucinations the odds are again very
low that it is schizophrenia in a non-inpatient environment, and presumably even lower in a noninpatient environment that is also a substance rich environment. For example, consider the
prevalence rates for visual hallucinations of patients with schizophrenia are between 16-72%.
The higher rates are gleaned from studies of patients in inpatient units, the lower rates are from
studies of those with a diagnosis in the general population, and if visual hallucinations are
present, auditory hallucinations are generally co-occurring, although not necessarily at the same
time. Given the prevalence of schizophrenia is estimated to be 0.7% according to the DSM-5
that would mean the prevalence rate for an individual to present with a symptom of visual
hallucinations is very low. In contrast between 7-25% of people presenting with psychotic
features for the first time are determined to have substance/medication use or withdrawal in
various populations. Also, considering the 23 year-old hallucinating at Mardi-Gras, it would be
prudent to know first if the patient had used substances. Then one would rule-out the most likely
life threatening causes by utilizing the simplest and most accurate measure, which has the lowest
false positive rate. This spotlights another consideration: the base rate for diagnostic validity and
specificity within a population.
Regarding diagnostic validity and specificity, for the point of this discussion I am going
to move from the Mardi-Gras example and consider Alzheimer’s disease. The gold standard of
diagnostic accuracy for Alzheimer’s disease is diagnosis based on autopsy findings. Not an ideal
method of diagnostic accuracy when one hopes a patient to survive. This highlights the
importance of balancing patient safety and diagnostic accuracy. However, prior to autopsy with
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what specificity and sensitivity may diagnosis be made? The answer is so low as to recognize
that it is generally diagnosed as probable Alzheimer’s disease.
Considering, psychological diagnoses with what specificity and validity is a diagnosis of
schizophrenia made? What is the gold standard of diagnosis? What are the sensitivity and
specificity of diagnostic measures? There have been multiple attempts to identify biological
markers and early identifiers of schizophrenia and there is to date no gold standard of diagnosis
(American Psychiatric Association, 2013). What are the base rates for false positives, false
negatives, and diagnostic accuracy? As psychologists we diagnose based on what we believe we
know and what we have learned as psychologists about symptom criteria that diagnoses describe,
as well as what we know about the patient. We often take a history (psychiatric, social, and
medical) of the patient and perhaps the patient’s family during a formal or informal interview,
and if possible we may collect collateral information. From this information, clinicians attempt
to determine what happened or changed prior to onset (e.g., was the onset acute or slow and
insidious). Then we rule out likely alternate causes. Then clinicians compare the cluster of
symptoms to the diagnostic cluster of symptoms accepted at the time as the diagnostic definition
and determine whether what has been observed or reported fits the diagnosis. Clinicians may use
psychological and neuropsychological assessment for diagnostic clarification as well. After
diagnosis, if clinicians remain in contact with the patient, which may be a big if given many
patient populations and clinical settings, clinicians the attempt to determine if the course of the
disorder is as expected and responds to treatment as expected, or does not.
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Neuropsychological/Psychological Assessment
As stated above, as a part of differential diagnosis clinicians may use psychological
assessment and/or neuropsychological assessment measures. The DSM-5 hallucination
diagnostic decision tree lists neuropsychological performance as a factor to consider at several
diagnostic junctures. Neurocognitive domains that may be assessed with neuropsychological
assessment include complex attention, executive function, learning and memory, expressive and
receptive language, perceptual motor abilities, and social cognition. Valuable data may be gained
from testing to help inform the level of functioning and diagnosis, when compared to the
patient’s history and current level of functioning. However, regarding neuropsychological
assessment it is important to remember the diagnostic validity and specificity of the assessment
measures used.
Regarding the degree to which a measure tests what it is claiming to test (validity), the
probability that a test accurately identifies those who do have the specific diagnosis (specificity)
and the degree to which the test accurately identifies a negative diagnosis for those who do not
have the diagnosis (American Psychological Association, 2007), it is important to remember the
conclusion of the 1996 Neuropsychology Assessment panel:
No neuropsychological tests have been shown to have consistent diagnostic validity.
Some tests accurately distinguish between two or three diseases when samples of patients
with these diseases are assessed, but no study has shown that neuropsychological tests
have positive predictive values when a wide variety of disorders are tested” (593).
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Neuropsychological tests provide data that can be used as part of the diagnostic process,
but no neuropsychological test supersedes the judgment of the clinician. Tests may be used to
help quantify or describe a current level of function, but not to predict.
In addition, researchers often mistake “the null hypothesis in research designs and group
statistics (e.g. means, standard deviations, correlation coefficients, etc.) for research that directly
quantifies how well (or how poorly) our tests actually quantify individuals” (Smith et al, p 40).
This is said not to undercut the utility and value of neuropsychological testing in differential
diagnosis, but to reiterate that group norms of expected performance of patients with a given
disorder may be very similar to patterns of performance of groups of patients with other
disorders as well, or even groups without identified disorders. Also, part of neuropsychological
testing performance looks at deviation from the norm the individual has from the population, and
what is expected given the patient’s age and education. Individual testing performance can be
influenced by anxiety, sleep deprivation, sickness, medication, pain, and many other variables.
Even in “normals” being tested there is significant deviation from the norm by one standard
deviation. As stated by Binder, Grant and Iverson:
Abnormal performance on some proportion of neuropsychological tests in a battery is
psychometrically normal. Abnormalities do not necessarily signify the presence of
acquired brain dysfunction because low scores and large intra-individual variability often
are characteristic of healthy adults. We recommend that test battery developers provide
data on the amount of variability in normal samples and also provide base rate tables with
false positive rates that can be used clinically when interpreting test performance (2009,
p.31).
For example the base rate for a 25-point score discrepancy on the Working Memory
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Index for someone with an IQ score in the 90-109 range on the Wechsler Adult Intelligence
Scale, Forth Edition (WAIS –IV )is 10.7%. Another study addressing flexible
neuropsychological batteries found “most (73%) of the healthy older adults had one or more
scores at or below the 10th percentile and 37% had one or more scores at or below two standard
deviations from the mean” (Binder, Iverson, & Brooks, 2009, p. 31; Palmer et al., 1998). Again,
this is stated not to diminish the potential utility of testing, but to remind clinicians of what
assessment can and cannot do.
Visual Hallucination
At the first branch of the DSM-5 Hallucination Decision Tree one is to determine whether
the symptom is a hallucination. Hallucination is defined in the DSM-5 as “a perception-like
experience with clarity and impact but without the external stimulation of the relevant sensory
organ” (American Psychiatric Association, 2013, p. 822). The DSM-5 further clarifies the
definition by stating that visual hallucinations are to be distinguished from misperceptions or
misinterpretations of an external event as occur in illusions. This definition does not sufficiently
take into account attribution error, nor does it truly clarify what a visual hallucination is.
Perception, imagination, and hallucination are identical in that they may all be classified as
perception behaviors. They all involve the same behavior of seeing. However, in perception that
which is seen is in front of you; in imagination it is not and you know it is not; in hallucination it
is not but you think it is. The same behavior of seeing is happening whether the scene is there or
not (Karson, 2006). Patients with insight regarding their hallucinations are often hesitant to tell
providers of their hallucinatory experiences for fear of being seen as having a psychiatric
condition (Shea, 1998). Also, if a patient readily acknowledges that what was seen was not
there, would this not be classified as a visual aberration instead of a visual hallucination?
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Conversely, patients without insight are likely to not report hallucinations because they are
unaware their experiences are hallucinatory. It is up to the provider to observe if a patient is
acting as they are responding to a visual hallucination and to question about visual hallucinations
in a manner that is open and reduces perceived stigma about hallucinations (Zuckerman, 2010;
Shea, 1998). Providers must also consider whether there is potential gain to be obtained by the
report and consider the possibility of malingering in such cases (Lezak, Howieson, Loring,
Hannay, & Fischer, 2004).
Visual hallucinations with formed objects such as people are called complex
hallucinations. Those with unformed images such as auras, light flashes, or patterns are called
simple hallucinations (Moore & Puri, 2012). Visual hallucinations that occur during the daytime
and do not occur immediately before or after sleep have a lifetime prevalence rate of 3.2% in the
general population (Ohayon, 2000). Hallucinations that occur while falling asleep (hypnogogic)
or waking (hypnopompic) are considered “within the range of normal experience” (American
Psychiatric Association, 2013, p. 88). Almost one-third of the general population may experience
complex visual hallucinations while in the state proceeding or following sleep (Ohayon, 2000).
However, although complex hallucinations affect normal populations, they also occur in
pathological condition (Manford & Adermann, 1998). Visual hallucinations have a bimodal
distribution prevalence with respect to age. Psychosis related visual hallucinations occur more
often in late adolescence and early adulthood. Visual hallucination related to neurodegenerative
disorders, and eye disease occur more frequently in elderly populations (Waters et al., 2014).
Visual hallucinations may be a symptom of non-affective and affective psychiatric
disorders, such as schizophrenia, bi-polar disorder, or depression (American Psychiatric
Association, 2013). Often patient report of visual hallucinations does generate psychiatric
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consultation, even though visual hallucinations “are not pathognomonic of a primary psychiatric
illness” (Teeple et al., 2009, p. 26). Although a feature of psychosis and often considered
psychiatric in nature, the etiology of visual hallucinations is greatly varied, as are the appropriate
treatments and interventions.
Visual hallucinations are frequently indicators of a number of neurologic and medical
conditions such as seizures, metabolic or endocrine disorders, and infection, as well as substance
intoxication or withdrawal, rather than indicative of psychiatric disorder (Cummings & Miller,
1987; Duwe & Turetsky, 2002; Hall, Popkin, Devaul, & Faillace, 1978; Sacks, 2013; Shea,
1998; Teeple et al., 2009). Hallucinations due to neurological or medical disorders often are
distinguishable from schizophrenia spectrum disorders by having a higher prevalence of
prominent visual hallucinations, and a lower prevalence of bizarre behavior, thought disorder,
rapid speech, and negative symptoms (Cornelius et al., 1991). However, the prevalence of visual
hallucinations is higher than previously believed in psychiatric conditions (Waters et al., 2014).
If and how visual hallucinations are etiologically related in psychosis, neurodegenerative
disorders and eye disease remains unclear (Waters et al., 2014).
There are multiple mimics of psychiatric dysfunction that should be considered when a
patient initially presents with visual hallucinations (Teeple et al, 2009; Shea, 1998; Duwe &
Turetsky, 2002). When a patient presents with a visual hallucination, one should suspect organic,
medical or toxin etiologies (Shea, 1998). Disturbances in sleep are linked to visual
hallucinations, even if a formal diagnosis of sleep disorder or narcolepsy is not present. Visual
hallucinations linked to sleep disturbance are also found in Parkinson’s disease, PTSD,
peduncular seizures, Lewy Body dementia, stoke, migraine, epilepsy, Charles Bonnet syndrome,
and schizophrenia (Manford & Adermann, 1998).
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Accurate diagnosis of the etiology of visual hallucinations can be difficult, especially
given similar presentations between disorders, co-morbid conditions, and the low prevalence
rates of many of the potential etiologies. Prompt medical evaluation is recommended with the
initial presentation of psychotic features, particularly if onset is acute with no prior history of
hallucination or other psychotic features (Hall, Popkin, Devaul, & Faillace, 1978; Shea, 1998).
Proper diagnosis and treatment is crucial, as misdiagnosis of those with visual hallucinations can
have profound and even life threatening consequences. Even with careful psychiatric
interviewing, medical examination and diagnosis, misdiagnosis does happen. A clinician should
be aware of treatment effectiveness and what does not fit the clinical and psychological picture
and re-evaluate (Shea, 1998). For example, schizophrenia and narcolepsy can have similar
symptom presentations and can be difficult to differentially diagnose (Talih, 2011). Studies have
indicated that patients with narcolepsy have been misdiagnosed with schizophrenia, placed in
psychiatric hospitals and treated with anti-psychotic drugs; in fact, antipsychotic drugs may
increase the psychotic features, including visual hallucinations in patients with narcolepsy. An
incorrect diagnosis can contribute to a cycle of psychiatric symptoms, hospitalization, decreased
quality of life, and economic and societal impact continued in some cases for years until the
correct diagnosis was identified and the incorrect treatment ceased. This is just one example of
the potential profound impact of misdiagnosis.
Given that neuropsychological testing, neurological imaging, lab tests and psychological
testing all have their limitations regarding validity, specificity, and base rates of inaccurate
diagnosis, and that norms for testing are based on the group norms, the psychiatric interview is
an important diagnostic tool. The interview should obtain pertinent information regarding the
patient’s age, substance/medication use and/or discontinuation, medical history, psychiatric
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history, presence, onset, type of onset, behavioral, psychiatric, mood, or cognitive symptoms,
estimated pre-morbid functioning, family medical, psychiatric and neurological histories.
Attribution error and malingering should also be considered.
Questions to be considered at this juncture are:
1. Is the event described a hallucination, misperception, illusion, or imagination?
2. Is there attribution error on the part of the patient or clinician?
3. Is the hallucination hypnogogic or hypnopompic or not?
4. What type of hallucination is it, complex or simple?
5. Is insight intact? If so, how did the person identify the hallucination or visual
aberration?
6. Is the hallucination disturbing to the patient?
7. What is the context of the hallucination?
8. What was the duration of the hallucination?
9. What does the patient believe the consequences of the hallucination are?
10. Are other hallucinations or delusions present?
11. Are there negative symptoms?
12. Is there potential gain or secondary gain?
13. Is this the first time a visual hallucination has presented? If not, what were the
previous hallucinations and in what context?
Substance/Medication Induced Visual Hallucinations
The next juncture of the decision tree asks the clinician to determine whether the
visual hallucination is due to the physiological effects of a substance/medication. Substance or
medication use and/or withdrawal symptoms are statistically a likely cause of visual
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hallucinations. Substance use among patients presenting with first episode of psychosis is two
times that of the general population (Barnett et al., 2007). Substance use is present in the
majority of people presenting with first episode psychosis (Barnett et al., 2007), and “between 725% of individuals presenting with a first episode of psychosis in different settings are reported
to have substance/medication induced psychotic disorder,” with the higher rates reported in
emergency room settings (American Psychiatric Association, 2013). However, it is possible that
people with new onset psychotic disorders are more likely to use substances.
Distinguishing between substance-related psychotic symptoms and primary psychotic
illness is critical, because each requires different treatment. Some cases may require treatment
with medication and medication may be contraindicated in other cases. Studies indicate that
visual hallucinations were more common with substance related psychotic symptoms and that
negative symptoms of psychosis were more frequently related with primary psychosis. However,
studies also indicate, "psychotomimetic drug use may precipitate a chronic schizophrenic illness"
(Caton et al., 2005, p. 143). According to the DSM-5 substance or medication induced psychotic
disorder has unknown prevalence rates in the general population. Studies have indicated a
prevalence rate of diagnosed substance induced psychotic disorder in the general population of
0.43% (Perala et al., 2007). However, one should note that the statistic for those with diagnosed
substance induced psychotic disorder does not include those with substance withdrawal,
substance withdrawal delirium, substance intoxication, or substance intoxication delirium, all
which may present with visual hallucinations. In my first year as a practicum student I noticed a
patient in his 50’s looking around the room while I was speaking to him following surgery.
When I asked him what he saw, he described seeing a mouse. There was no mouse, but he was
unaware that he was beginning to have hallucinations related to alcohol withdrawal. When
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admitted to the hospital for surgery he had denied regular alcohol use. In fact he denied alcohol
use until the unreality of the hallucination symptoms, the course of treatment and potential risks
of alcohol withdrawal were described to him. Fortunately, when the patient was faced with
potential medical complications his wife provided his heavy alcohol use history, and treatment
with benzodiazepines ensued.
Besides denial of substance use or withdrawal patients and/or providers may be unaware
of or fail to research substance/medication interaction (Zuckerman, 2010), or the interaction may
be unknown. For example, suppose that you have a patient taking 16 prescribed medications, as
well as herbal supplements and vitamins; it is likely that given all the permutations of substance
interaction there are no available studies researching someone taking those 16 medications and
additional supplements. The interactions and side effects may be unknown, particularly in an
older patient who is medically compromised. Patients may also not take their medication as
prescribed. Given these variables it is important for the clinician to keep substance/medication
use or withdrawal in mind even after the initial consultation, particularly if the clinical picture
remains unclear and psychological data does not fit the pattern of hallucinations and behavior.
Symptoms of substance/medication intoxication and withdrawal include autonomic
hyperactivity, pupillary dilation, nystagmus, sweating, increased hand tremor, insomnia, nausea,
hallucinations, psychomotor agitation, anxiety, generalized tonic seizures, impaired judgment,
and confusion.
Drugs and medications associated with visual hallucinations include street drugs such as
alcohol, cocaine, PCP, methylenedioxymethamphetamine (Ecstasy), amphetamine, mescaline, dlysergic acid diethylamide (LSD), opioids, and cannabis; psychotropic medications such as
benzodiazepines, L-dopa, dopaminergic, neuroleptic, anti-cholinergic, serotonergic, sedative,
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anxiolytic, tricyclic antidepressants, benztropine, narcotics; non-psychotropic medications such
as digoxin, glucocorticoids, amantadine, cimetidine, ranitidine, sildenafil, beta-blockers,
clarithromycin; and over the counter drugs such as ephedrine and phenylpropanolamine (Liu,
Volpe, & Galletta, 2001; APA, p. 482) . Substance/medication related visual hallucinations are
one of the few horses in the diagnostic decision tree and combined with medical implications
they should be a primary consideration and rule-out.
Alcohol is the most commonly used drug associated with visual hallucinations. It is
estimated that 12.4% of adult men and 4.9% of adult women have alcohol substance use
disorder. It is also estimated that approximately 50% of middle-class individuals with alcohol
use disorder experience full alcohol withdrawal syndrome and more than 80% of those with
alcohol use disorder who are hospitalized or homeless may experience withdrawal. Transient
visual, auditory, and tactile hallucinations may accompany withdrawal. Hallucinations may occur
outside of delirium. Less than 10% of those will develop alcohol withdrawal delirium or
withdrawal seizures (American Psychiatric Association, 2013). However, the answer to the
question as to whether or not substance/medication use or withdrawal is involved can be more
difficult to determine than one may initially anticipate. This determination is important because
withdrawal from alcohol can be fatal for heavy drinkers, and if necessary, medical treatment
should begin as soon as possible.
Even before we have considered other substances such as stimulants, hallucinogens,
opioids, sedatives, cannabis, and other medication, it is of note that it is statistically more likely
for substance/medication involvement than psychiatric disorder alone. Also important
statistically is the higher prevalence of substance use by young adults (American Psychiatric
Association, 2013). The prevalence rate of substance abuse among people with severe mental
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illness is significantly higher than that in the general population. Diagnostic accuracy is
particularly critical in the onset of a psychiatric disorder, at a time when the clinical picture may
be clouded by substance use (Caton et al., 2005). Diagnostic stability is also a question. Those
diagnosed with drug-induced psychosis generally fall into one of two categories. Either the
patients are discharged with no follow up for several years or they have a longer hospital stay,
are referred to log-term follow-up care and have a change in diagnoses (Komuravelli, Poole, &
Higgo, 2011). In addition to diagnostic accuracy, substance use history is also important because
it is strongly correlated with non-compliance to psychiatric treatment (Weiss, Smith, Hull,
Courtney, & Huppert, 2002).
Regarding this juncture of the decision tree, it is important to consider:
1. Which substances/medications have been used or discontinued?
2. Are signs of autonomic disturbance, agitation, tremor, and other indicators of
withdrawal apparent?
3. Is medical referral necessary due to risk to patient?
4. If substances are related, is there also a co-morbid psychiatric condition?
5. You may not be getting the truth regarding substance use, continue to watch for
signs of substance involvement, even if initially denied.
6. Substance use/withdrawal related hallucinations often are visual, tactile and
auditory and are usually transient, but may persist.
7. Prevalence rate amongst the general population in various settings is 7-25%.
8. The prevalence rate of substance use among young adults is higher, and
prevalence rate of medication use among older adults is higher.
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9. Substance use is much more frequent among those with primary psychiatric
disorders than the general population.
10. Medications such as antipsychotic and psychotomimetic medications may be
contraindicated.
Visual Hallucinations Due to Physiological Effects of Medical Condition
The next juncture of the DSM-5 hallucination decision tree asks the clinician to
determine if the hallucination is due the physiological effects of a medical condition and then to
consider whether the patient presents with fluctuating attention and awareness, indicating
delirium, or with neurocognitive impairment in at least one cognitive domain such as complex
attention, executive function, social cognition, perceptual motor ability, language, learning and
memory. The DSM-5 has reclassified Dementia, Delirium, Amnestic, and Other Cognitive
Disorders as Neurocognitive Disorders (NCD). Visual hallucinations related to physiologic
conditions may range from simple to complex and the patient may or may not have insight that
the hallucination is a hallucination and not real. As with determining whether a hallucination is
substance or medication related, determining if a hallucination is due to a medical condition is
crucial as some of the conditions associated with visual hallucinations are life threatening and
prompt treatment is imperative (Shea, 1998; Teeple et al., 2009).
Delirium
The clinician is first asked to determine whether the patient is experiencing delirium.
Delirium is a medical condition and can indicate life threatening medical disorders. Delirium is
defined as a “disturbance of attention or awareness that is accompanied by a change in baseline
cognition that cannot be better explained by existing or evolving neurocognitive disorder”
(American Psychiatric Association, 2013, p. 599). The change develops over a short period of
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time from a few hours to a few days and may fluctuate over the course of a day (American
Psychiatric Association, 2013). However, delirium is not always acute in onset and it is possible
for onset to be insidious (Shea, 1998).
In the general population the prevalence of delirium is 1-2%, but it is as high as 14% in
those over 85 years of age. The prevalence of delirium in patients at hospital admission ranges
from 14%-24%. Prevalence rates for delirium during hospitalization range from 6%-56% in
general hospital settings and 70%- 87% of older individuals in intensive care. Prevalence rates
for delirium at the end of life are as high as 83% for all individuals.
Delirium may precede stupor, coma, and death if underlying causes are not treated.
Mortality rates among those hospitalized with delirium are as high as 40%. Deliriums
characterized by vivid hallucinations, delusion, language disturbance, and agitation must be
distinguished from psychotic disorders (American Psychiatric Association, 2013, p.600).
Estimations of prevalence of visual hallucinations among delirious patients are as high as 75%
(Cummings & Miller, 1987). The presence of visual hallucinations should prompt a provider to
strongly consider organic origins or delirious states. Fear and anxiety are often present with
atypical affect. Orientation and short-term memory are frequently impaired and illogical thought
or loosening of associations may appear. Delirious patients may frequently identify someone
unfamiliar, such as a new doctor, as being someone familiar. Deliria tend to fluctuate and often
worsen at night, which is called “sundowning” (Shea, 1998, p. 326). Delirium may be difficult to
distinguish from other neurocognitive disorders, particularly in individuals with unrecognized
neurocognitive disorders. Furthermore, a delirium may be superimposed on another
neurocognitive disorder. However, delirium is often recognized by acuteness of onset,
fluctuation of course, and often disturbance in the sleep/wake cycle (American Psychiatric
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Association, 2013). Common causes of delirium are infection, metabolic disorders, neurologic
disorders, post-operative sequelae, and substance/medication intoxication or withdrawal.
Infections can be intracranial such as encephalitis of meningitis, or systemic, such as urinary
tract infection, pneumonia, septicemia, typhoid and malaria. Common metabolic disorders
include electrolyte imbalance, hyperglycemia, hypoglycemia, hypoxia, hypercarbia, anemia,
abnormal levels of calcium or magnesium, vitamin-B deficiency, liver or kidney disease, and
endocrine disorders such as hyperthyroidism, hypothyroidism, and adrenal disorders. Neurologic
disorders that may cause delirium include trauma, seizures, stroke, hypertensive crisis,
subarachnoid hemorrhage, and vasculitits (Shea, 1998). Even in patients with known psychotic
disorder, if their psychotic presentation generally presents in similar manner and then presents in
an atypical manner, additional etiology should be considered, because delirium warrants
aggressive medical evaluation and this may be overlooked in patients with chronic psychiatric
conditions. The provider should especially attend to significant problems with attention and
fluctuating levels of consciousness (Shea, 1998).
Considerations at this juncture include:
1. Does the patient meet criterion for delirium with disturbance in attention and
awareness?
2. Is immediate medical referral and intervention necessary for the safety of the
patient?
3. Has this type of delirium occurred before and in what circumstances?
4. What is the course of the appearance of psychiatric dysfunction?
5. Are there co-morbid conditions?
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6. Is this the appropriate time to diagnose psychiatric dysfunction or should the
course of the delirium be assessed?
7. Review medical/psychiatric records if possible to help rule out probable medical
causes as, well as psychiatric causes.
8. Assess patient’s performance with a mini-mental status exam or other quick to
administer and score repeatable measure, so that scores can be compared to each
other over a short time period.
9. Even if the patient has a psychiatric history, if the symptoms are different and
consistent with delirium, rule-out delirium.

Mild and Major Neurocognitive Disorders
According to the DSM-5, “The Neurocognitive Disorders (NCDs) are unique among
DSM-5 categories in that there are syndromes for which the underlying pathology, and
frequently the etiology as well, can potentially be determined” (p. 591). This statement brings
forth several questions. First if the etiologies are able to be determined, why not label them as
such using the appropriate medical code that is already in place versus using two to three codes
with additional specifiers? The question is also raised as to the utility of such general diagnoses
as Mild NCD. The diagnosis of Mild NCD seems highly sensitive, not specific, and without a
reliable gold standard. All that is required to meet diagnostic criteria is (a) evidence of a modest
decline from a previous level of performance in one cognitive domain (complex attention,
executive function, learning and memory, language, perceptual–motor, or social cognition) based
on concern from the individual, a knowledgeable informant, or a clinician, and (b) that the mild
decline in cognitive function be preferably documented by neuropsychological testing, or in its
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absence, by another quantified clinical assessment (American Psychiatric Association, 2013).
Questions of what constitutes modest decline and other quantified clinical instrument are raised,
given that the base rates for “normals” to have declines of one standard deviation is
psychometrically normal. The clinician is then to specify if possible whether the NCD is due to:
Alzheimer’s disease, frontotemporal lobar degeneration, Lewy body disease, vascular disease,
traumatic brain injury (TBI), substance/medication use, HIV infection, Prion disease,
Parkinson’s disease, Huntington’s disease, another medical condition, multiple etiologies or
unspecified etiology. Finally the diagnoses of Major and Mild NCD contains rule outs that the
cognitive deficits are not better explained by another mental disorder. What if there is a comorbid mood disorder that occurs? What if there are symptoms of mood disorder within the
medical diagnosis? What if a patient with a mood disorder does have impairment in cognitive
domains? Does that not merit charting as a neurocognitive disorder, especially given the general
nature of the NCD diagnosis and the lack of appropriate cognitive functioning specifiers of the
mental disorders? Finally the DSM-5 hallucination decision tree does not consider the
possibility of visual hallucinations due to a medical condition without neurocognitive disorder.
The DSM-5 even recognizes that “the differential diagnosis between normal cognition and mild
NCD, as between mild and major NCD is challenging because the boundaries are inherently
arbitrary” (p.610). Major NCD is comparable to dementia of the DSM-IV and prevalence rate at
65 years of age is estimated at 1-2% and as high as 30% by age 85 (p.608). The DSM-5 states
that estimates for Mild NCD are comparable with the previous prevalence estimates of mild
cognitive disorder in the DSM-IV of “2-10% at age 65 and 5-25% by age 85” (p. 608). However,
since Mild NCD is so close to normal functioning as to be difficult to differentiate, prevalence
rates could be quite high. Given the change in diagnostic criteria from dementia there are no
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prevalence rates available for the general Mild NCD. Which again raises the question of the
utility of the diagnosis of Mild NCD.
Considerations at this juncture include:
1. Is there a medical condition that better explains the psychiatric symptom of
visual hallucination?
2. Has the patient had recent medical care?
3. Is a referral recommended?
4. Is neuropsychological testing necessary or is medical diagnostic testing
necessary?
5. Does the patient’s medical or psychiatric diagnostic history identify a potential
etiology?
6. Is this psychiatric presentation consistent with previous diagnosis and
previous psychiatric symptoms if any?
7. Are there other neurologic symptoms?
8. Are there any psychiatric symptoms?
9. Are psychiatric symptoms consistent with a psychiatric diagnosis, or
inconsistent, potentially indicating alternate diagnosis?
10. As with other junctures of the decision tree consider age and the prevalence
rate for the most likely conditions given the patient’s presentation and age.

Visual Hallucinations and Medical Disorders
An awareness of medical diagnoses that mimic psychiatric disorders and may present
with visual hallucinations is important to keep in mind, in addition to the physiological and
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medical etiologies of delirium. This list is in no way complete, but rather a short list of the
medical diagnoses that most often present with visual hallucinations. The prevalence rates of
these disorders will be presented. Disorders to be discussed include Lewy body disease,
Parkinson’s disease, Alzheimer’s disease, vascular dementia, narcolepsy, Huntington’s disease,
Creutzfeldt-Jakob disease, migraine, epilepsy, seizure, stroke, and traumatic brain injury, as well
as vision loss related, retinal pathology, and Charles-Bonnet syndrome (Cummings & Miller,
1987; Liu, Volpe, & Galetta, 2010; Teeple et al., 2009). The diagnoses below, which often
present with visual hallucinations, are not to be confused with the diagnosis of psychotic disorder
due to a general medical condition. The diagnosis of psychotic disorder due to a medical disorder
“is generally not diagnosed” if reality testing regarding the hallucinations is maintained or the
patient can appreciate that the hallucinations are part of a medical condition. The prevalence rate
of psychotic disorder due to medical condition is estimated at 0.22% (Perala et al., 2007).
Neurological disorders
Parkinson’s Disease
Prevalence rates for Parkinson’s disease are 0.3-0.4% for the general population, up to 4.5 % for
the population of those over age 85 (Blin et al., 2015). Prevalence rates for visual hallucinations
among those diagnosed with Parkinson’s disease are between 6-40% depending on those studied.
Lower rates are indicated in the general population and higher rates in medical and assisted
living settings, as well as at later stages of the disease. Prevalence of mild neurocognitive
disorder (Mild NCD) is 27% among those diagnosed with Parkinson’s disease. Visual
hallucinations related to Parkinson’s disease may be due to the disease process, medication
effects, or sleep disturbance (Liu et al., 2010).
Lewy Body Disease
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In the general elderly population prevalence rate estimates for neurocognitive disorder
with Lewy bodies range from 0.1%-5.0%. This rate is higher in men than in women by a ratio of
1.5:1. Lewy Body disease accounts for 1.7-35% of all dementia cases. Lesions known as Lewy
bodies are present in 20%-35% of autopsy confirmed dementias. Core features of the disease
include two out of three of the following features: recurrent well formed visual hallucinations,
fluctuating cognition with changes in attention and alertness, spontaneous features of
parkinsonism with the onset of cognitive decline (American Psychiatric Association, 2013, p.
619). It is estimated that over 77% of patients with Lewy Body dementia have visual
hallucinations (Del Ser et al., 2000, p. 1034). Hallucinations may become disabling and lead to
nursing home placement (Liu et al., 2010). Accurate diagnosis is essential because up to 50% of
those with NCDLB have neuroleptic drug sensitivity. Other symptoms of Lewy Body disease
include orthostatic hypotension, autonomic dysfunction, transient loss of consciousness, urinary
incontinence, syncope, repeat falls, auditory and non-visual hallucinations, delusions, apathy,
REM sleep disturbance, and depression (American Psychiatric Association, 2013; Del Ser et al.,
2000). The onset of Lewy Body dementia is insidious in the sixth to ninth decades of life. Most
cases occur in the seventh decade of life and the course of the disease progression is usually
between five to seven years (American Psychiatric Association, 2013). Lewy Body dementia is
distinguished from Parkinson’s dementia by disease course and onset. In Lewy Body dementia
the onset of cognitive decline precedes the motor symptoms of Parkinson’s disease by at least
one year. It can also be difficult to differentiate Lewy Body dementia from Alzheimer’s disease
as these diseases are frequently is co-morbid, especially in the oldest age groups (American
Psychiatric Association, 2013)
Alzheimer’s Disease
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Prevalence of visual hallucinations among patients with Alzheimer’s disease is between
3-33%. Visual hallucinations account for 85% of the hallucinations associated with this disorder.
According the to 2014 Alzheimer’s Association report, it is estimated that one in nine people
over the age of 65 has Alzheimer’s disease. Of those affected, two-thirds are women
(Alzhiemer's Association, 2014). In the context of Alzheimer’s disease, visual hallucinations are
generally associated with increased cognitive decline and poor prognosis. Delusions, paranoia,
and auditory hallucinations may also be present (American Psychiatric Association, 2013).
Treatment options for Alzheimer’s disease are limited. Neuroleptic medications may be
used for Alzheimer’s patients with visual hallucinations, but anticholinergic medications may be
contraindicated should be monitored (Liu et al., 2010).
Stroke
The Stroke Association reports that an estimated one percent of those diagnosed with
stroke may experience psychotic features of hallucinations or delusions. Visual hallucinations
following a stroke generally start within a few days of the stroke. The hallucinations may subside
in a few weeks, but they may also be present for years. Peduncular visual hallucinations are
generally related to mid-brain injury and may be complex, vivid and lifelike. Stroke related
visual hallucinations are often co-occur with sleep disturbance, ataxia, and cognitive disturbance
(Liu et al, 2010).
Migraine
Visual hallucinations with migraine are usually simple and consist of aura, spectra,
squiggles, dots, prisms, halos, or flashing lights usually followed by a headache. Auras are the
most common and occur in approximately one-third of migraine patients. These typically last
from a few minutes to an hour, but may last for up to a week. Vaso-constriction induced cortical
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ischemia were originally thought to cause auras, but recent research has suggested neuronal
dysfunction from cortical depression. Complex visual hallucinations of people and animals, and
visual distortions such as size distortions of one’s own body or surroundings do occur with
migraines, albeit rarely (Liu et al., 2010).
Epilepsy/Seizures
Visual hallucinations are not uncommon in patients with epilepsy. Studies indicate that
among patients with occipital lobe epilepsy 60% have simple hallucinations (Liu et al., 2010).
Visual field defects are associated with occipital lobe epilepsy, but patients may be unaware of
their deficit. Complex hallucinations are more frequently associated with temporal lobe epilepsy
but are reported by 10% of patients with occipital lobe epilepsy. Between 16-18% of patients
with temporal lobe epilepsy have visual hallucinations. However, hallucinations in temporal lobe
epilepsy are more likely to involve other senses than those of the occipital lobe. Visual
hallucinations associated with parietal lobe epilepsy are uncommon (Liu et al., 2010).
Narcolepsy
The prevalence of narcolepsy in the general population is 0.01-0.18% (Talih, 2011).
Narcolepsy usually affects those between ages 5-55, but it is most prevalent among those in their
20s (Liu et al, 2010). Narcolepsy may be overlooked and misdiagnosed for years before the
correct diagnosis is made (Cummings & Miller, 1987) and the appropriate treatment given
(Duwe & Turetsky, 2002; Talih, 2011). Patients with narcolepsy may view themselves as having
a psychiatric disorder prior to correct diagnosis. Patients have reported not realizing that their
hallucinations were related to a sleep disorder since they could occur during the day where
patients were unaware that they were momentarily going in and out of sleep states (Sacks, 2013;
Cummings & Miller, 1987).
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Visual hallucinations occurring in narcolepsy are generally complex and often associated
with auditory and tactile hallucinations. The duration of these visual hallucinations is variable,
ranging from a few seconds to minutes. They often occur regularly: for some on a daily basis.
Insight is usually, but not always intact. When insight is compromised, hallucinations may be
misattributed to some other cause in order to make sense of them (Sacks, 2013). Patients may
appear to have unusual, magical thinking, or delusional thinking as well (Ohayon, 2000; Sacks,
2013; Szucs, Jansky, Hollo, & Migleczi, 2003). Symptoms associated with narcolepsy include
hypnogogic hallucinations, excessive daytime cataplexy, sleepiness, or sleep paralysis (Szucs et
al., 2003; Talih, 2011).
There are tests available to identify narcolepsy, including measurement of hypocretin
levels in cerebrospinal fluid, huford leukocyte antigen (HLA) typing, and mean sleep latency
testing (MSLT). Treatment for narcolepsy typically includes wake promoting agents and central
nervous system stimulants. Selective serotonin reuptake inhibitors and serotonin norepinephrine
reuptake inhibitors may be used when cataplexy is a part of the clinical picture. However,
antipsychotic drugs are often contraindicated in the treatment of narcolepsy (Talih, 2011, p.31).
Vision Impairment and Visual Hallucinations
Complex visual hallucinations with insight occur among those with acquired visual
impairment. These hallucinations are not related to chronological age and the individuals may be
cognitively intact (Menon, 2005) and psychologically normal (Teunisse, Zitman, Cruysberg,
Hoefnagles, & Verbeek, 1996). Many of the patients with visual impairment associated with
hallucinations have reported that they would not have told their physicians about having
hallucinations, if not asked directly, for fear of being thought to have a psychiatric illness or
dementia (Holroyd, Rabins, Finkelstein, Nicholson, Chase, & Wisniewski, 1992; Menon, 2005).
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Training physicians to educate patients and ask in a manner that does not suggest psychiatric
illness may be helpful (Holroyd et al., 1992). Patients found reassurance in learning that their
visual hallucinations did not represent additional pathology (Menon, 2005).
Macular Degeneration
Estimated prevalence rate for visual hallucinations amongst those with age-related
macular degeneration is 13%. Significant variables include bilateral vision loss, particularly with
visual acuity of 20/60 or worse, living alone, history of stroke, and lower scores on cognitive
testing (Holroyd et al., 1992).
Retinal Disease
Prevalence rate for visual hallucinations in patients with retinal disease is 15%. These
hallucinations last from a few seconds to minutes (Scott, Schein, Feuer, & Folstien, 2001).
Charles Bonnet Syndrome
Charles Bonnet syndrome is characterized by complex release hallucinations in
psychologically normal individuals. The release hallucination is a spontaneous visual response,
which may be due to lack of inhibitory input such as seen with hallucinations by prisoners of war
who experienced sensory deprivation. Charles Bonnet syndrome has been used as a catchall term
for diagnosing those with release visual hallucinations who were considered psychologically
normal. Most patients with diagnosed Charles Bonnet syndrome have incurred vision loss. Those
with Charles Bonnet syndrome typically have macular degeneration, cataracts, diabetic
retinopathy, glaucoma, or corneal disease (Liu et al., 2010). The hallucinations experienced may
last from a few seconds to hours. Estimated prevalence rates among those who have visited an
ophthalmologist is less than 0.5% (Shiraishi, Terao, Ibi, Nakamura, & Tawara, 2003). The
estimated prevalence rate among those with low vision is between 12.8%-17.5% for complex
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visual hallucinations and 50% for simple visual hallucinations (Reichert, Series, & Storkey,
2013).
Conversion Disorder
At this juncture the DSM-5 diagnostic decision tree for hallucinations asks the clinician
to consider conversion disorder. However, there are no prevalence rates available for transient
conversion disorder. The incidence for persistent conversion symptoms is estimated to be 25/100,000 or 0.00002% to 0.00005%. Dissociative symptoms are more common in the disorder.
Although visual hallucinations may occur in conversion disorder, they are not listed as a primary
symptom. Visual symptoms such as tunnel vision are listed as possible diagnostic features.
Comorbid conditions common with conversion disorder include depressive disorders, anxiety
disorders, somatic symptom disorder, personality disorders, neurologic disorders and other
medical conditions. A history of trauma is also common with conversion disorder. Conversion
disorder is more common in women. Ruling out neurological disease, somatic symptom disorder,
factitious disorder, dissociative disorder, body dysmorphic disorder, and panic disorder is part of
differentially diagnosing conversion disorder. Given the low incidence rate, other potential
diagnoses should be considered first.
Culturally Sanctioned Visual Hallucinations
The next juncture asks the clinician to determine if a hallucination is culturally sanctioned. For
example in the United States visual hallucinations as a part of a grief response are not considered
pathological. Grief hallucinations occur across cultures. Visual hallucinations of “seeing” the
deceased are usually brief. Prevalence rates for hallucinations related to grief response are
estimated from 10% to 41%; Rates are higher among those who are widows or widowers after
age 40. These rates are between 23% to 41% for college students. Prevalence rates of visual
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hallucinations are higher in those with pathological conditions such as PTSD, Charles Bonnet
syndrome, or reactive psychosis (Collerton, Mosimann, & Perry, 2015). Clinicians should weigh
the degree to which a patient is having these hallucinations. Is it a brief vision of the loved one as
a potential part of the psychological process of mourning, or is the person having long periods of
imagining their loved one there with them, unaware that they are not actually with them? Just
because the subject matter of the hallucination may be culturally sanctioned does not mean the
etiology behind the hallucination is not pathological.
Psychotic Disorders
Visual hallucinations occur in psychiatric disorder, including schizophrenia spectrum
disorders, bi-polar disorder with psychotic symptoms, depression with psychotic symptoms, and
brief psychotic disorder. In psychiatric disorders, auditory hallucinations are more common than
visual hallucinations, and visual hallucinations are generally, but not always accompanied by
auditory or tactile hallucinations, although not necessarily simultaneously. The duration of
hallucinations in psychiatric disorder is variable. The lifetime prevalence for all psychotic
disorders is between estimated between 3- 3.5% (Perala et al., 2007).
Affective Disorders with Psychotic Features
The next two junctures of the decision tree ask the clinician to determine whether the
symptoms occur in the context of a manic or depressed mood. Estimated prevalence rates for
Bipolar I Disorder with psychotic features (which may or may not include visual hallucinations)
is 0.24%. The estimated prevalence rate for Major Depressive Disorder with psychotic features is
0.35% (Perala et al., 2007). The estimated prevalence rate for visual hallucinations among
patients diagnosed with affective disorders with psychotic features is 15% (Waters et al., 2014).
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The junctures for affective psychotic disorders are listed in the decision tree before
schizophrenia spectrum disorders. However, it is important to remember that prevalence rates
indicate that visual hallucinations with these disorders are statistically less common than visual
hallucinations with schizophrenia spectrum disorders.
Schizophrenia Spectrum Disorders
The next junctures asks the clinician to consider nonaffective/schizophrenia spectrum
psychiatric disorders by assessing length of time psychotic symptoms have been present, and by
assessing for delusions, disorganized speech, grossly disorganized or catatonic behavior, and
negative symptoms of schizophrenia spectrum disorders.
Schizophrenia. Schizophrenia has a lifetime prevalence rate in the general population of
0.3% to 0.87%. Research has indicated some variance in rates by ethnicity and race (American
Psychiatric Association, 2013; Perala et al., 2007). Between 16% to 72% of individuals
diagnosed with schizophrenia have visual hallucinations: the higher percentages are from studies
of individuals on inpatient units (Mueser, Bellack, & Brady, 1990) and often occur with auditory
hallucinations. Comparatively, 74% of people with a diagnosis of schizophrenia experience
auditory hallucinations (Sartorius, Shapiro, & Jablensky, 1974). International studies indicate
that culture impacts hallucination prevalence rates: auditory hallucinations are universally more
common among those diagnosed with schizophrenia across cultures with prevalence rates from
66% to 90.8%. Visual hallucinations were far less prevalent with rates between 3.9% to 53.9%.
The highest prevalence rates for both types of hallucinations were found in Nigeria and Ghana
(Bauer et al., 2011, p. 322).
Onset is typically in the late 20s for females and early to mid 20s for males. “Late onset
cases can still meet diagnostic criteria for schizophrenia, but it is not yet clear whether this is the
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same condition as schizophrenia diagnosed prior to mid-life” (American Psychiatric Association,
2013, p. 103). Males tend to have more negative symptoms than females. Impaired cognition is
common even when other symptoms are not active. Neuropsychological research has indicated
abnormalities associated with schizophrenia, but none diagnostic. No laboratory or psychometric
tests conclusively identify schizophrenia (American Psychiatric Association, 2013). Medical
comorbidity of patients with a diagnosis of schizophrenia should be considered. Studies have
indicated that some patients' mental symptoms are caused or exacerbated by undiagnosed
medical conditions (Jeste, Gladsjo, Lindamer, & Lacro, 1996).
Schizoaffective. Schizoaffective disorder has a lifetime prevalence rate of 0.3%. As with
schizophrenia, hallucinations are more commonly auditory, but may be visual. The general
course is two months of auditory hallucinations or delusions followed by a depressive period. It
is important to remember that part of the diagnosis is a major mood episode of either bipolar or
depressive type. Differentiating schizoaffective disorder from mood disorder with psychotic
features can be challenging. The distinguishing criteria are major mood episode present the
majority of the duration of active and residual symptoms, as well as two or more weeks of
delusions or hallucinations when no major mood episode is present. Onset is generally in early
adulthood but can occur anywhere from adolescence to late life. Females are diagnosed with
schizoaffective disorder more frequently than males and have more depressive symptoms
(American Psychiatric Association, 2013).
Schizophreniform. Incidence of schizophreniform disorder is low. In the United States it
is “possibly five-fold less than schizophrenia” with an estimated prevalence rate of 0.07%
(American Psychiatric Association, 2013, p. 98). Approximately one-third of those diagnosed
with schizophreniform disorder will recover in 6 months. “The majority of the remaining two-
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thirds will eventually receive a diagnosis of schizophrenia or schizoaffective disorder”
(American Psychiatric Association, 2013, p. 98). Information on prevalence rates of visual
hallucinations related to schizophreniform disorder is lacking.
Other Schizophrenia Spectrum and Other Psychotic Disorders
At this juncture the clinician is asked to consider other schizophrenia spectrum and
psychotic disorders. However, no other criteria are suggested. In this diagnosis the clinician is to
document and specify the presenting psychotic symptom. The clinician is to also document why
full criteria are not met. Unspecified schizophrenia spectrum and other psychotic disorders are
vague as to diagnostic criteria and the DSM-5 states that this diagnosis is made when a clinician
chooses “not to specify the reasons that schizophrenia spectrum or other psychotic disorder
criteria are not met.” Prevalence rates for these diagnoses are unavailable. These diagnoses lack
diagnostic clarity and their utility is limited, outside of documentation.
Brief Psychotic Disorder
At this juncture the clinician is asked to consider brief psychotic disorder if symptoms are
present more than one day but less than one month. Brief psychotic disorder accounts for 9% of
cases of first-onset psychosis. This disorder may occur at any age, but may be more common in
the 30s and in patients with personality disorders or personality disorder traits.
Important considerations regarding possible psychiatric related visual hallucinations
include:
1. Age of the patient.
2. Does age of onset of symptoms suggest schizophrenia?
3. Is there a history of auditory hallucinations?
4. Are there negative symptoms?
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5. Are there delusions?
6. Is there disorganized speech?
7. Is there disorganized or catatonic behavior?
8. Does the patient have insight regarding the hallucinations?
9. If the patient does not have insight what is the response to having the event
labeled a hallucination?
10. Is the onset of symptoms: acute or insidious?
11. What is the duration of the symptoms?
12. Do the symptoms occur within or outside of mood disorder?
13. Are the hallucinations hypnopompic or hypnogogic?
14. What occurred before onset of symptoms, any changes?
15. If the patient has a history of affective or nonaffective psychiatric disorder, are the
symptoms different this presentation?
16. Substance/medication use and discontinuation history
17. Medical history of the patient
18. Psychiatric history of the patient
19. Patient’s family medical, neurologic, and psychiatric history
20. History of head injury
21. Trauma history
22. Educational history
23. Social and work history
24. Is the patient an accurate historian?
25. Is psychological or neuropsychological testing suggested?
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Additional Psychiatric Considerations
Trauma related flashbacks should be distinguished from visual hallucinations. PTSD has
high comorbidity with other psychiatric disorders. If visual hallucinations are present other
medical, psychotic, and personality disorders should be considered (American Psychiatric
Association, 2013).
Hallucinations Not Covered Above
At this juncture the DSM-5 decision tree asks the clinician to consider diagnoses not
covered earlier in the diagnostic decision tree, without any guidance as to possible etiologies
except to reconsider a schizophrenia disorder or psychotic disorder if there is clinically
significant impairment or distress. Even though the visual hallucinations may be one symptom of
psychosis they “are not pathognomonic of a primary psychiatric illness” (Teeple et al., 2009, p.
26), even if clinically significant and causing distress. Note that there are no guidelines as to
what defines “clinically significant” or “distress.” The logic at this juncture is somewhat circular
and is prone to attribution error given the lack of diagnostic sensitivity or specificity, and does
not acknowledge that the etiology of the majority of psychiatric conditions is unknown
(American Psychiatric Association, 2013). Also the utility of diagnoses at this juncture is limited.
The decision tree does not allow for the consideration of referral to another medical specialist
and does not allow for lack of knowledge of the etiology of the visual hallucination.
The alternate diagnosis or lack of diagnosis at this point is “nonpathological,” which
according to the decision tree indicates that the visual hallucination does not cause significant
clinical impairment or distress. This may or may not be true. For example, a patient may not
have distress regarding visual hallucinations, but that patient may have a medical or psychiatric
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condition that has yet to be identified. Again this juncture does not allow for the consideration of
many of the possible conditions described in this paper, or the unknown.
Considerations at the final junctures include:
1. Review data for what could have been missed. Could the hallucination be related
to unknown or unrecognized medical disorders, psychiatric disorders, or
substance/medication use or withdrawal?
2. Are there accompanying neurologic symptoms?
3. Is a medical referral in order?
4. Is referral to another clinician in order?
5. Is the hallucination related to sleep disturbance?
6. What does the visual hallucination mean to the patient?
7. What is the function of the hallucination?
8. What is the context of the hallucination?
9. Inform and educate the patient regarding possible medical, substance/medication,
metabolic, ophthalmologic, psychiatric, and neurologic etiologies.
10. Inform the patient that you do not know the cause.
11. Consider possible secondary gain.
Conclusion
Differential diagnosis related to the symptom of visual hallucinations can be challenging
given the wide variety of underlying etiologies, potential health risks, and consequences
associated with both the underlying etiology, as well as potential damage of misdiagnosis and
incorrect treatment. Although visual hallucinations are generally perceived to be a symptom of
psychiatric disorder, they are more commonly associated with neurological or medical disorders,
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sensory impairment, or substance intoxication or withdrawal. In this paper I summarized the
most prevalent causes of visual hallucinations, reviewed the DSM-5 hallucination decision tree,
and provided an annotated visual hallucination differential diagnosis decision tree. It is in no way
inclusive of all the causes of visual hallucinations, underlying mechanisms, or treatment options.
The causes of visual hallucinations are too numerous, and the treatment options too varied to
cover in the scope of this paper. However, it is my hope that this paper may serve as a reminder
of those causes, which are both psychiatric and non-psychiatric so that trainees like myself may
be more aware and open to diagnoses outside of our training to help limit attribution error related
to psychiatric diagnosis. Also I hope it serves as a reminder to re-examine diagnosis when the
course of the symptoms is not as expected and response to treatment is not as expected.
Information related to visual hallucination prevalence is limited and unavailable for many
disorders. This may be in part due to the fact the many patients do not report visual
hallucinations out of fear of being seen as having psychiatric disorder. Also, data may be limited
by clinicians assuming that visual hallucinations are psychiatric or organic in nature depending
on the specialty and diagnostic frame of the clinician. The data that is available is from multiple
studies over many decades. During that time diagnostic criteria have been altered and additional
diagnoses have been discovered. For example, it is likely that some individuals studied as having
schizophrenia in older studies may now be recognized as having had a stroke or dementia with
Lewy bodies. It is important to remember that diagnoses change and that a diagnosis often is
used in a top to bottom approach, which may lead to attribution error. Keeping in mind
prevalence rates is one way to help check attribution error. However, it is likely that studies of
prevalence rates may also be influenced by attribution error and diagnostic error.
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Figure 1.0. DSM-5 Handbook of Differential Diagnosis Decision Tree for Hallucinations

48

VISUAL HALLUCINATION DIFFERENTIAL DIAGNOSIS CHART

49

VISUAL HALLUCINATION DIFFERENTIAL DIAGNOSIS CHART

50

Reprinted from DSM-5 Handbook of Differential Diagnosis, by Michael B. First, 2014, Decision
tree for hallucinations, pp.46-48. Copyright 2014 by the American Psychiatric Association.

